Close Menu

Amgen

Lower, But…

A trial of a drug that mimics a PCSK9 gene mutation doesn't quite meet expectations, both Nature News and Forbes say.

In PLOS this week: mitochondrial mutation linked to tubulointerstitial kidney disease, asthma protection variant, and more.

The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL. 

The company plans to use the funds to build up a Dublin-based genomic research and development program based on the model of Iceland's Decode Genetics.

The deal follows a June agreement under which Exosome is developing an exosomal RNA sequencing platform with Takeda.

A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.

DeCode Genetics' Kari Stefansson and his colleagues uncovered a dozen genetic variants that influence blood lipids, and explored links to coronary artery disease.

Amgen has posted three of its failed efforts to confirm findings from high-profile journal articles online to encourage others to do likewise.

The tests analyze tumor samples for mutations oncogenes including KRAS and NRAS in order to help guide treatment decisions for patients with metastatic colorectal cancer.

DeCode's Kari Stefansson and his colleagues report that creativity and conditions like schizophrenia and bipolar disorder share a genetic source.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.